Zydus Lifesciences Limited

BSE:532321 Stock Report

Market Cap: ₹1.0t

Zydus Lifesciences Past Earnings Performance

Past criteria checks 5/6

Zydus Lifesciences has been growing earnings at an average annual rate of 21.4%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 8.2% per year. Zydus Lifesciences's return on equity is 18.3%, and it has net margins of 19.9%.

Key information

21.4%

Earnings growth rate

21.8%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate8.2%
Return on equity18.3%
Net Margin19.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zydus Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:532321 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24214,83542,77745,2510
30 Jun 24206,15341,68543,9880
31 Mar 24195,47438,36542,4570
31 Dec 23190,24129,56240,2380
30 Sep 23187,76028,10938,9550
30 Jun 23184,12725,26238,1430
31 Mar 23172,37419,64937,6490
31 Dec 22164,33520,78534,5720
30 Sep 22157,11019,62933,5940
30 Jun 22153,36121,71033,0720
31 Mar 22151,09922,41632,4980
31 Dec 21157,60923,26733,8690
30 Sep 21157,38923,26934,1550
30 Jun 21156,13022,60033,7160
31 Mar 21144,03522,01631,2500
31 Dec 20150,07618,46533,8820
30 Sep 20148,50116,93233,7380
30 Jun 20143,96713,27033,5500
31 Mar 20142,53111,76633,0800
31 Dec 19142,33812,44830,6520
30 Sep 19141,73613,81629,7020
30 Jun 19137,68216,91928,9470
31 Mar 19131,65618,48828,3150
31 Dec 18126,70619,95426,9620
30 Sep 18123,52620,30526,3770
30 Jun 18126,13321,16825,8010
31 Mar 18119,04917,94624,8740
31 Dec 17111,69115,70523,0760
30 Sep 17102,20613,51122,1780
30 Jun 1793,39712,27715,7180
31 Mar 1793,76514,90420,7740
31 Dec 1697,49411,32322,8400
30 Sep 1697,97112,81222,1100
30 Jun 1697,22114,18613,8630
31 Mar 1694,26819,33919,8750
31 Dec 1595,90114,84326,7490
30 Sep 1592,45313,76626,7440
30 Jun 1589,79512,63826,2770
31 Mar 1586,51311,50619,0600
31 Dec 1482,95510,39424,7400
30 Sep 1479,7779,43524,1840
30 Jun 1476,1658,48824,0410
31 Mar 1472,0348,03623,7710

Quality Earnings: 532321 has high quality earnings.

Growing Profit Margin: 532321's current net profit margins (19.9%) are higher than last year (15%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 532321's earnings have grown significantly by 21.4% per year over the past 5 years.

Accelerating Growth: 532321's earnings growth over the past year (52.2%) exceeds its 5-year average (21.4% per year).

Earnings vs Industry: 532321 earnings growth over the past year (52.2%) exceeded the Pharmaceuticals industry 20.5%.

Return on Equity

High ROE: 532321's Return on Equity (18.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:37
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zydus Lifesciences Limited is covered by 69 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited